Asthma affects millions of people worldwide and remains one of the most common chronic respiratory conditions. For many patients, controlling asthma symptoms and preventing exacerbations can be challenging, especially when other serious illnesses such as cancer are also present. New research presented at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting suggests that certain cancer treatments called immune checkpoint inhibitors may actually help reduce asthma flare ups in some patients.
The findings provide early evidence that therapies used in oncology could have additional immune system benefits beyond cancer treatment. While the results are still preliminary, they offer encouraging insights for patients who live with both asthma and cancer.
This article explains the study findings, how immune checkpoint inhibitors work, and what the results could mean for asthma management in the future.
Asthma is a chronic inflammatory disease that affects the airways in the lungs. When someone with asthma encounters triggers such as allergens, infections, cold air, or pollution, the airways become inflamed and narrow. This can cause symptoms including:
An asthma exacerbation refers to a sudden worsening of symptoms that often requires additional medication or emergency medical care. Preventing these flare ups is a major goal in asthma treatment because frequent exacerbations can reduce quality of life and increase the risk of hospitalization.
Patients with moderate to severe asthma may require multiple medications such as inhaled corticosteroids, bronchodilators, and biologic therapies to keep symptoms under control.
Immune checkpoint inhibitors are a class of drugs used primarily in cancer treatment. These medications help the immune system recognize and attack cancer cells more effectively.
Normally, immune checkpoints act as regulators that prevent the immune system from attacking healthy cells. Cancer cells sometimes exploit these checkpoints to avoid detection. Immune checkpoint inhibitors block these signals, allowing immune cells to target tumors more efficiently.
Two commonly used checkpoint inhibitors include:
Both medications are widely used to treat cancers such as melanoma and renal cell carcinoma.
Because these drugs influence immune system activity, researchers have become increasingly interested in whether they may affect other immune related conditions, including asthma.
Researchers analyzed electronic health records from the TriNetX US Collaborative Network to evaluate how immune checkpoint inhibitors might influence asthma outcomes.
The retrospective cohort study included 2,329 adult patients between ages 18 and 80 who had both asthma and cancer. All participants were receiving immune checkpoint inhibitor therapy for either melanoma or renal cell carcinoma.
Asthma subtypes were classified using ICD 10 diagnostic codes. Researchers then compared asthma exacerbation rates at three time points after treatment began:
These results were also compared with matched control patients who did not receive immune checkpoint inhibitors.
The study revealed several important insights about the relationship between immune checkpoint inhibitor therapy and asthma exacerbations.
Across all asthma types, patients receiving pembrolizumab or nivolumab experienced a modest reduction in exacerbation rates after 24 months.
Although the difference is relatively small, it was statistically significant and suggests a potential protective effect.
The most notable improvements were observed among patients with moderate to severe persistent asthma.
In this group, the results showed:
This indicates a more substantial reduction in asthma flare ups for patients with more severe disease.
Patients receiving a dual therapy combination of nivolumab and ipilimumab did not demonstrate a meaningful difference in exacerbation rates compared with controls.
This suggests that not all checkpoint inhibitor regimens have the same impact on asthma symptoms.
Scientists believe immune checkpoint inhibitors may influence asthma through immune system modulation.
Asthma is closely linked to immune activity and inflammation in the airways. Since checkpoint inhibitors alter how immune cells respond to threats, they may also indirectly affect inflammatory pathways involved in asthma.
However, researchers emphasize that the exact mechanisms remain unclear. More research is required to determine why these medications appear to reduce exacerbations in some patients.
Possible explanations include:
Future studies will need to examine these possibilities in more detail.
One of the most important takeaways from the study is that moderate to severe asthma may not need to be considered a contraindication for immune checkpoint inhibitor therapy.
Previously, physicians sometimes worried that these treatments could worsen inflammatory conditions like asthma. The new findings suggest this may not be the case.
For patients who require checkpoint inhibitors for cancer treatment, the research indicates that asthma symptoms may remain stable or even improve.
However, treatment decisions must always be individualized. Doctors will consider many factors such as:
Patients should always discuss potential risks and benefits with their healthcare provider before starting any new therapy.
While the findings are promising, the study has several limitations.
First, it was a retrospective observational analysis, which means researchers reviewed existing medical records rather than conducting a controlled clinical trial.
Second, electronic health record data may contain inconsistencies or incomplete information.
Third, the study population consisted of patients with specific cancers, so the results may not apply to all individuals with asthma.
Because of these limitations, researchers stress that prospective clinical trials are necessary to confirm the relationship between immune checkpoint inhibitors and asthma outcomes.
The study highlights an emerging area of research that connects oncology and respiratory medicine.
If future studies confirm these findings, immune checkpoint pathways could potentially become a target for new asthma therapies.
Researchers are particularly interested in understanding whether the immune mechanisms involved in cancer treatment could also be harnessed to reduce airway inflammation in asthma.
Although such treatments are still hypothetical, the concept opens exciting possibilities for the future of asthma care.
The growing use of immune checkpoint inhibitors in cancer treatment has led researchers to explore their broader effects on the immune system. Early evidence suggests that medications like pembrolizumab and nivolumab may modestly reduce asthma exacerbations, particularly in patients with moderate to severe asthma.
While more research is needed to confirm these findings and explain the underlying biology, the study provides encouraging news for individuals managing both asthma and cancer.
Understanding how immune based therapies interact with chronic inflammatory diseases may ultimately lead to improved treatment strategies across multiple medical fields.
This article is for informational and educational purposes only and should not be considered medical advice. The content summarizes research findings and does not replace consultation with a qualified healthcare professional. Patients should speak with their doctor or a licensed medical provider regarding diagnosis, treatment options, and any medical concerns.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.